Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.

ABSTRACT:

Background

Doxorubicin is one of the most commonly used chemotherapeutic drugs for breast cancer; however, its use is limited by drug resistance and side effects. We hypothesized that adding FTY720, a sphingosine-1-phosphate (S1P) receptor functional antagonist, to doxorubicin would potentiate its effects by suppression of drug-induced inflammation.

Materials and methods

The Cancer Genome Atlas, Gene Expression Omnibus data sets, and National Cancer Institute-60 panel were used for gene expressions and gene set enrichment analysis. E0771 syngeneic mammary tumor cells were used. OB/OB mice fed with western high-fat diet were used as an obesity model.

Results

STAT3 expression was significantly increased after doxorubicin treatment in human breast cancer that implicates

SUBMITTER: Katsuta E 

PROVIDER: S-EPMC5661979 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature